Semaglutide 7 mg and 14 mg tablets are now available for reducing the risk of cardiovascular death, heart attack, or stroke ...

The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of ...

Novo Nordisk (NVO) stock is in focus as the FDA OKs a label revison for the company's GLP-1 pill Rybelsus to cut ...

Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in ...

Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular ...

Analysts believe that while the deal is positive, Cipla's share price is unlikely to see a fresh run-up, given the rise it ...

Discover why Viking Therapeutics, Inc.'s VK2735 could lead GLP-1 obesity drugs. Click for my updated look at VKTX stock ...

Two newly approved medications expand options beyond lifestyle modifications for metabolic dysfunction-associated steatotic ...

The FDA has approved oral semaglutide (Rybelsus) 7 mg and 14 mg tablets to lower the risk of cardiovascular death, heart attack, or stroke in high-risk adults with type 2 diabetes-marking the ...

MariTide is now progressing into phase 3 trials, with a focus on its long-term safety and efficacy. Amgen expects to apply ...

Cipla enters obesity and diabetes drug market with Eli Lilly's tirzepatide 'Yurpeak'; Nuvama retains 'Hold' on Cipla stock, ...

GLP-1 inhibitors, like tirzepatide, show promise in reducing AHI in OSA patients with obesity, as demonstrated in the SURMOUNT trials. Experts highlight the importance of integrating GLP-1s with diet ...